The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
LENZ Therapeutics Inc (NASDAQ: LENZ) closed the day trading at $17.08 down -5.84% from the previous closing price of $18.14. In other words, the price has decreased by -$5.84 from its previous closing price. On the day, 2.32 million shares were traded. LENZ stock price reached its highest trading level at $19.62 during the session, while it also had its lowest trading level at $16.63.
Ratios:
For a better understanding of LENZ, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.63 and its Current Ratio is at 12.69. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 18, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $60.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $37.Raymond James initiated its Outperform rating on September 27, 2024, with a $37 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when Olsson Shawn sold 10,000 shares for $26.10 per share. The transaction valued at 261,022 led to the insider holds 4,733 shares of the business.
SHAWN OLSSON bought 40,000 shares of LENZ for $1,024,000 on Nov 17 ’25. On Nov 07 ’25, another insider, MCCOLLUM JAMES W, who serves as the Director of the company, bought 10,500 shares for $22.79 each. As a result, the insider paid 239,278 and bolstered with 10,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LENZ now has a Market Capitalization of 534432640 and an Enterprise Value of 333214656. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.54 while its Price-to-Book (P/B) ratio in mrq is 2.52. Its current Enterprise Value per Revenue stands at 19.041 whereas that against EBITDA is -4.922.
Stock Price History:
The Beta on a monthly basis for LENZ is 0.58, which has changed by -0.44029623 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, LENZ has reached a high of $50.40, while it has fallen to a 52-week low of $15.70. The 50-Day Moving Average of the stock is -44.33%, while the 200-Day Moving Average is calculated to be -45.22%.
Shares Statistics:
Over the past 3-months, LENZ traded about 1.09M shares per day on average, while over the past 10 days, LENZ traded about 1341860 shares per day. A total of 28.59M shares are outstanding, with a floating share count of 28.17M. Insiders hold about 9.98% of the company’s shares, while institutions hold 91.17% stake in the company. Shares short for LENZ as of 1764288000 were 7959225 with a Short Ratio of 7.27, compared to 1761868800 on 7229614. Therefore, it implies a Short% of Shares Outstanding of 7959225 and a Short% of Float of 43.8.
Earnings Estimates
The stock of LENZ Therapeutics Inc (LENZ) is currently in the spotlight, with 5.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.87 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$2.45 and -$2.74 for the fiscal current year, implying an average EPS of -$2.64. EPS for the following year is -$2.88, with 6.0 analysts recommending between -$1.99 and -$3.65.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $3.57M. There is a high estimate of $4.3M for the next quarter, whereas the lowest estimate is $2.3M.
Based on 7 analysts’ estimates, the company’s revenue will be $52.26M in the next fiscal year. The high estimate is $60.59M and the low estimate is $41.17M.
